GSK To Pay $150M To Settle Direct Purchasers' Flonase Suit
GlaxoSmithKline agreed to pay $150 million to end a direct purchaser antitrust class action accusing GSK of filing sham petitions with the U.S. Food and Drug Administration to delay generic alternatives...To view the full article, register now.
Already a subscriber? Click here to view full article